Loading…
Employees: 44
Size Surrozen (SRZN) is a United States Health Care company (Biotechnology) with a market value of $364M, the 2941st largest of 3,117 United States companies the cockpit tracks. Shares closed at $16.16 on 6 Nov 2026.
Performance Over six months the shares fell 35.4%, against -23.2% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue fell 8.8% over the last twelve months (peer median -3.5%); the operating margin is -385.3% (peer median -856.9%).
Valuation It trades at 23.3× enterprise value to sales against a peer median of 14.4× (7th most expensive of 16).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $11.5M | $3.48M | $10.7M | $0 | $12.5M |
| Revenue growth | — | -67% | — | -100% | — |
| Gross profit | $11.3M | $2.94M | $9.21M | -$1.91M | $9.23M |
| EBITDA | -$44.1M | -$41.6M | -$24.1M | -$41.1M | -$41.1M |
| Net income | -$350M | -$242M | -$63.6M | -$43.0M | -$36.0M |
| Free cash flow | -$35.0M | -$30.4M | -$17.7M | -$40.8M | -$44.9M |
| Capital expenditure | $222,000 | $128,000 | $26,000 | $398,000 | $728,000 |
| Total debt | $6.32M | $6.64M | $8.47M | $3.38M | $5.60M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SRZN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.6% | -7.7% | 3rd lowest of 20 |
| 6-month return | -35.4% | -23.2% | 7th lowest of 19 |
| Distance from 52-week high | -53.8% | -51.2% | 9th lowest of 20 |
| Revenue growth (TTM) | -8.8% | -3.5% | 7th lowest of 16 |
| Operating margin | -385.3% | -856.9% | 8th highest of 16 |
| EV / Sales | 23.3× | 14.4× | 7th most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | 7.1× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | 14.4× | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |